Post-chemotherapy neuropathy

Neuropatia pós-quimioterapia

Ricardo Caponero1, Emily Santos Montarroyos2, Silvia Maria Machado Tahamtani3

ABSTRACT

BACKGROUND AND OBJECTIVES: Anticancer chemotherapeutics can induce painful peripheral neuropathy. Symptoms range widely and can involve sensory, motor, and autonomic systems. However, chemotherapy-induced peripheral neuropathy is under-assessed and undertreated and its diagnosis is somewhat complicated by the lack of consensus on its pathophysiology and presentation. The objective of this study was to review medical publications in English, Spanish and Portuguese, in the last ten years, about painful peripheral neuropathy.

CONTENTS: Systematic literature review on painful peripheral neuropathy associated with systemic anticancer chemotherapy.

CONCLUSION: Although limited reliable evidence regarding the appropriate treatment for this condition exists, it is based on current neuropathic pain guidelines. Further studies on differences between the pathophysiology of chemotherapy-induced peripheral neuropathy and those of other neuropathic pain conditions may lead to the development of more effective treatment modalities. Additionally, therapeutic strategies for the management of chemotherapy-induced peripheral neuropathy must be validated by large-scale randomized clinical trials to meet the demands of evidenced-based medicine.

Keywords: Adverse effects, Chemotherapy, Neopathy, Neuropathic pain.

RESUMO

JUSTIFICATIVA E OBJETIVOS: A quimioterapia antineoplásica pode induzir a neuropatia periférica dolorosa. Os sintomas variam amplamente e podem envolver o sistema sensitivo, motor e autonômico. Contudo, a neuropatia periférica induzida por quimioterapia é subvaluada e subtratada e tem um diagnóstico posterigado pela falta de um consenso em sua fisiopatologia e apresentação. O objetivo deste estudo foi revisar trabalhos publicados em português, inglês ou espanhol nos últimos 10 anos, a respeito da fisiopatologia e tratamento da neuropatia periférica dolorosa.

CONTEÚDO: Revisão bibliográfica, sistemática, sobre neuropatia periférica dolorosa associada à quimioterapia sistêmica antineoplásica.

CONCLUSÃO: Embora existam limitadas evidências confiáveis a respeito do tratamento apropriado dessa condição, ela é fundamentada nas diretrizes gerais para o tratamento da dor neuropática. Estudos subsequentes devem levar em consideração as diferenças na fisiopatologia da neuropatia periférica induzida pela quimioterapia de outras condições de neuropatia dolorosa, que possam levar ao desenvolvimento de modalidades de tratamento mais efetivas. Adicionalmente, estratégias terapêuticas para o tratamento de neuropatia periférica induzida por quimioterapia precisarão ser validadas em estudos clínicos randomizados de larga escala, a fim de satisfazer as demandas da medicina baseada em evidências.

Descritores: Dor neuropática, Efeitos adversos, Neopatia, Quimioterapia.

INTRODUCTION

Anti cancer chemotherapy-induced peripheral neuropathy (IPN) is an adverse event present in approximately 38% of patients being treated with multiple agents, although this percentage may vary depending on drug, dose, exposure duration, comorbidities (especially alcoholism and diabetes), association with other treatments (surgery, radiotherapy, etc.) evaluation methods and time it takes to appear with regard to anti-cancer treatment.1 A literature review involving 31 studies and 4179 patients has shown prevalence of chemotherapy-induced neuropathy of 68.1% (95% confidence interval (CI95%): 57.7% – 78.4%) when measured in the first month after chemotherapy; 60.0% (36.4% - 81.6%) at three months; 30.0% (6.4% - 53.5%) at six months or more.3 Standardization of evaluation methods is critical for the accurate determination of incidence, grade and impact on quality of life (QL).1 Characteristically, neuropathy is associated to dysesthesia and pain, which affect QL and may become a very significant sequela for a long time in cancer survivors.4 Higher intensity presentations may result in decreased chemotherapy doses and early treatment interruption, thus impairing its efficacy. The importance of preventing and treating pain associated to chemotherapy-IPN increases as anti-cancer treatment provides and residual neuropathy after treatment may persist for a significantly long period, deteriorating survivors’ quality of life. Since 1970, the number of cancer survivors has tripled and today they are approximately 28 million worldwide and in whom late or long lasting adverse effects have major impact. Since potentially neurotoxic drugs are widely used for tumors of higher incidence, it is estimated the major impact of chemotherapy-IPN.5

NEUROPATHY-INDUCING CHEMOTHERAPEUTIC DRUGS

Combinations of chemotherapeutic drugs with highest peripheral neurotoxicity rates include those involving platinum salts (cisplatin, carboplatin and oxaliplatin), vinca alkaloids (vincristine, vinblastine, vinorelbine), bortezomib (proteasome inhibitor) and taxanes (paclitaxel, docetaxel, cabazitaxel).6 In addition to dose and time-dependent chronic neuropathy, some agents such as taxanes and oxaliplatin may induce a characteristic acute neuropathy syndrome triggered by cold and sometimes associated to pharyngolaryngeal dysesthesia. In this aspect, acute neurotoxicity which starts within hours or days after oxaliplatin infusion deserves special considerations.7 Oxaliplatin is primarily used to treat colorectal adenocarcinoma. Animal studies suggest changes in the level of regulatory and structural proteins in central nervous system (CNS) and spinal cord which may be directly implied in oxaliplatin-induced acute neurotoxicity.8 The combination of a platinum salt and a taxane is the treatment of choice for ovarian epithelial tumors. In this context, chemotherapy-IPN is often an adverse event of the treatment which may limit its administration and a new treatment cycle, thus impacting patients’ survival in case of recurrence, since neuropathy often lasts beyond the recurrence period.8 Bortezomib is a proteasome inhibitor used to treat recently diagnosed or recurrent myeloma and mantle cells lymphoma. Bortezomib-induced NP is considered its major non-hematologic toxicity, in general resulting in dose change do to its severity. Underlying mechanism is still not totally understood.9

PATHOPHYSIOLOGY

Although pathogenesis and toxicity profiles differ among potentially neurotoxic agents, there are some features which allow the differentiation of

1. Clínica de Oncologia Médica SC Ltda, Departamento de Oncologia, (Instituto de Estudios Biosanitários de Madrid), São Paulo, SP, Brasil.
2. Médica Anestesiologista com Área de Atuação em Terapia da Dor e Medicina Paliativa (SBA/AMB). Mestre em Medicina Tropical, Manaus, AM, Brasil.
3. Médica Anestesiologista e Alérgologista, Médica assistente no Centro Multidisciplinar de Tratamento da Dor - Instituto do Câncer do Estado de São Paulo. São Paulo, SP, Brasil.


Correspondence to:
Ricardo Caponero
Av. Nove de Julho, 4654 – Jardim Paulista (04060-100) São Paulo, SP, Brasil.
E-mail: riccapone@uol.com.br

© Sociedade Brasileira para o Estudo da Dor

DOI 10.5935/1806-0013.20160049
Chemotherapy-induced NP from those induced by other causes. Classically, many chemotherapeutic drugs causing peripheral neuropathy do it symmetrically, distal, with “boot and glove” distribution. This neuropathy is more sensitive than motor and symptoms are progressive and dependent on agents, doses and treatment duration. Different chemotherapeutic drugs affect different nervous system components, from dorsal root ganglion cells to the distal axon. Dorsal root ganglion, for being less protected by the nervous-blood barrier, is more vulnerable to neurotoxicity. This explains the predominance of sensory manifestation is patients affected by neuropathy. A common finding in nervous conduction studies is a sensory axonal injury with decreased action potentials amplitude, which may result from more complex cell changes resulting from mitochondrial alterations, interference with microtubules; qualitative neuronal membrane changes, oxidative stress and neuronal apoptosis.

Clinical presentation
Oxaliplatin-induced acute sensory neuropathy starts in a time interval which varies from drug administration moment to 3 to 5 days after it, may persist for days to months and have its intensity and duration increased with the sequence of treatment cycles. Its installation is acute and of rapidly progressing intensity, lasts for a variable period and tends to decrease in intensity some days later. Chemotherapy-INP pain affects more than 90% of patients under treatment, is in general triggered by cold, affecting distal limbs, mouth, jaw pain when biting and mouth paresthesia and may be simultaneous with pharyngolaryngeal dysesthesia. There might also be muscle spasms, fasciculations and cramps. Oxaliplatin chronic sensory neuropathy is dose-cumulative, with progressively increasing intensity along treatment, and is primarily manifested by sensitivity to cold, hypoaesthesia (numbness) and dysesthesia (tingling) in hands and feet, joint pain, muscle weakness and balance changes. It affects 30-50% of patients and may last for years after the end of chemotherapy. Patients adapt to chronic symptoms but sensory deficits last for a long time. Lack of support and follow up of these patients may lead them to depression, sleep disorders and significant QL impairment.

Bortezomib-induced NP is predominantly sensory, causing paresthesia and numbness in distal areas, especially lower limbs.

Diagnosis
As a function of characteristic clinical presentation and direct correlation with chemotherapy, diagnosis is often established by history and physical evaluation, not needing additional exams. Patients should be previously evaluated to identify other pre-existing sensory neuropathy causes, such as diabetic neuropathy. The correlation between onset and progression of neuropathic symptoms and chemotherapy duration also helps the identification of such patients. Electroneuromyography shows a predominantly sensory, peripheral and symmetrical neuropathy pattern. It seldom supplies data adding relevant information to clinical data, in addition to causing significant discomfort to patients.

Predictive factors of chemotherapy-induced peripheral neuropathy
Broad genoma analyses have described some single-nucleotide polymorphisms (SNP) associated with higher susceptibility, but are not applicable to current clinical practice. Different chemotherapeutic drugs affect different nervous system components, from dorsal root ganglion cells to the distal axon. Dorsal root ganglion, for being less protected by the nervous-blood barrier, is more vulnerable to neurotoxicity. This explains the predominance of sensory manifestation is patients affected by neuropathy. A common finding in nervous conduction studies is a sensory axonal injury with decreased action potentials amplitude, which may result from more complex cell changes resulting from mitochondrial alterations, interference with microtubules; qualitative neuronal membrane changes, oxidative stress and neuronal apoptosis.

In palliative treatment it is possible to withdraw medication when the adverse event becomes more evident, after considering the toxicity-benefit ratio. However, curative treatment regimens or those having major impact on disease evolution can be hardly replaced. Calcium glacone, magnesium taxasulfate, vitamins and other compounds have no proven efficacy to prevent neuropathy and are not recommended for this purpose. The only exception seems to be venlafaxine to prevent acute neuropathic pain specifically induced by oxaliplatin. Although there is improvement in the acute symptom, there are no evidences of the same benefit for chronic neuropathy.

According to the American Society of Clinical Oncology (ASCO) guideline, due to the lack of high quality data with consistent evidences, there is no agent recommended to prevent chemotherapy-induced NP.

Treatment
Neuropathic pain treatment shall be discussed in a different topic of this publication, but here one should stress neuropathic pain secondary to chemotherapy-induced NP because there is a specific guideline for it. According to ASCO, best available data on already installed chemotherapeutic-INP treatment support a moderate recommendation for treatment with duloxetine. Although chemotherapy-INP studies are inconclusive about tricyclic antidepressants (such as nortriptiline), gabapentin and other topic preparations with baclofen, amitriptyline and ketamine, these agents might be prescribed based on data supporting their usefulness for neuropathies of other causes.

A more recent systematic review and meta-analysis supports a review of recommendations for neuropathic pain pharmacologic therapy. Especially the number of patients needed to treat (NNT), combining the studies, is 6.4 (95% confidence interval (CI95%): 5.2 – 8.4) for serotonin and norepinephrine reuptake inhibitors, especially including duloxetine (9 out of 14 studies); 7.7 (6.5 – 9.4) for pregabaline; 7.2 (5.9 – 9.21) for gabapentin, including extended release formulation and enacarbil; and 10.6 (7.4 – 19.0) for patches with high capsaicin concentration. According to this review, considering costs and adverse events, findings provide strong recommendation for the use and the proposition as first line treatment for neuropathic pain of tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors, pregabaline and gabapentin. There is a weaker recommendation and a proposal for second line treatment for lidocaine patches or high capsaicin concentrations, and systemic tramadol. There is a weak recommendation and proposal for third line treatment for strong opioids.

Inadequate responses to neuropathic pain relief are a medical need not met for chemotherapy-INP patients. Modest efficacy, good responses to placebo, heterogeneous diagnostic criteria, variability in evaluation of efficacy and different phenotypes among patients are probably responsible for modest clinical trials results and shall be taken into consideration by further studies.

Data on the use of acupuncture or electroacupuncture, as well as natural products of complementary medicine do not supply enough evidence for any clinical recommendation to treat chemotherapy-induced neuropathic pain. Since there is no defined pharmacological treatment, if any, focus should be on patients' care and should promote education, explaining to patients and their families about potentially expected events; minimizing falls and risk of injuries due to hypoaesthesia; changing lifestyle and labor activities and avoiding risk factors worsening neuropathy.

CONCLUSION
Chemotherapeutic drugs with highest potential for adverse PNS events are among those most widely used, which makes peripheral sensory neuropathy a common event with major impact on patients' quality of life. It may lead to changes in treatment regimens with loss of effectiveness, as well as to chronic sequelae and incapacity. It is not always feasible to change anti-cancer therapeutic regimen, but early identification and adequate treatment of symptoms associated to peripheral sensory neuropathy may decrease its impact on QL. In patients under palliative care, the use of alternative regimens should be considered after weighing potential benefits versus adverse events.
REFERENCES